Telavancin

ABSTRACTVesicular systems provide large opportunities for the transdermal delivery of therapeutics. The present study was designed to investigate the potential of a novel class of vesicular system ‘proniosome’ as a carrier for transdermal delivery of telavancin. Proniosome formulations were prepared by co-acervation phase separation method. The developed system was characterized for drug release, zeta potential, particle size analysis and kinetics. Span 60 was the most appropriate surfactant, and yielded vesicle size and percentage encapsulation ef?ciency respectively. The in vitro telavancin proniosomes formulations exhibited a sustained release for 7 hrs. Zeta potential was found to be -32.7 mv which indicates the stability of the formulation. The proniosomes F6 formulation shows entrapment efficiency of 92.7%. From the diffusion study it was found that formulation F6 shows the highest drug permeation. F1 followed zero order release kinetic profile; F2 was first order release kinetic profile and for F3 to F7 followed Peppa’s model drug release kinetic profile. Formulations stored at refrigeration condition (8±2 °C) showed a higher drug entrapment when compared to the formulations stored at accelerated condition (30±2 0C) at (65±5%RH) after a period of 4 weeks. Keywords: Proniosomes, Telavancin, In vitro drug release and release kinetics